FindTrial
Sign In

Short course normal saline infusion in contrast-enhanced computed tomography for contrast-associated acute kidney injury (CA-AKI) prevention in CKD G3b patients: An open-label randomized controlled trial and incidence of subclinical CA-AKI using kidney biomarkers

Short course normal saline infusion in contrast-enhanced computed tomography for contrast-associated acute kidney injury (CA-AKI) prevention in CKD G3b patients: An open-label randomized controlled trial and incidence of subclinical CA-AKI using kidney biomarkers

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20221006001
Enrollment
192
Registered
2022-10-06
Start date
2023-04-18
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

There is a controversy to CA-AKI prevention in patients with elevated risk (CKD G3b) with short course normal saline infusion protocol with contrast-enhanced CT. Prevention is definitely useful for prevention of CA-AKI in CKD G4. contrast associated acute kidney injury,

Interventions

0.9%NaCL intravenous infusion 3 mL/kg/hr for 1 hour before and 1.5 mL/kg/hr for 4 hours after contrast-enhance CT ,No intravenous fluid infusion ad libitum water intake
Experimental Procedure/Surgery,No Intervention No treatment
Short course normal saline infusion,Standard of care

Sponsors

National Research Council of Thailand (NRCT)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 90 Years

Inclusion criteria

Inclusion criteria: CKD stage 3b that undergoing contrast-enhanced CT in Naresuan University hospital

Exclusion criteria

Exclusion criteria: Uncontrolled congestive heart failure Cardiomyopathy with EF < 30% Currently AKI from other causes Septic shock or hemodynamically unstable Pregnancy Refuse inform consent

Design outcomes

Primary

MeasureTime frame
Contrast associated acute kidney injury 48 h to 7 d serum creatinine,Receiver operating characteristic of contrast associated acute kidney injury 48 h to 7 d urinary neutrophil gelatinase-associated lipocalin, urinary liver-type fatty acid binding protein—

Secondary

MeasureTime frame
subacute contrast associated acute kidney injury 48 h to 7 d urinary neutrophil gelatinase-associated lipocalin, urinary liver-type fatty acid binding protein ,Receiver operating characteristic of contrast associated acute kidney injury 48 h to 7 d urinary neutrophil gelatinase-associated lipocalin, urinary liver-type fatty acid binding protein—

Countries

Thailand

Contacts

Public ContactTheerachai Thammathiwat

Faculty of Medicine, Naresuan University

theerachait@nu.ac.th0875563262

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026